Cargando…
Patient access to orphan drugs in France
BACKGROUND: Since incentives were introduced to promote orphan drugs in Europe, several dozens of drugs have been registered at the European level. However, patient access on a national level remains very heterogeneous across Europe. This can be explained by healthcare organization and drug reimburs...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6378733/ https://www.ncbi.nlm.nih.gov/pubmed/30777102 http://dx.doi.org/10.1186/s13023-019-1026-4 |